These data indicate that MET mutations promote the growth of endometrial tumors and show different sensitivities to cisplatin or tyrosine kinase inhibitors (crizotinib and SU11274), depending on the type of MET mutation. This evidence concerns the gene MET and endometrium neoplasm.